UY29456A1 - Heteroarilamidas(3.1.0)bicíclicas como inhibidores del transporte de glicina de tipo i - Google Patents
Heteroarilamidas(3.1.0)bicíclicas como inhibidores del transporte de glicina de tipo iInfo
- Publication number
- UY29456A1 UY29456A1 UY29456A UY29456A UY29456A1 UY 29456 A1 UY29456 A1 UY 29456A1 UY 29456 A UY29456 A UY 29456A UY 29456 A UY29456 A UY 29456A UY 29456 A1 UY29456 A1 UY 29456A1
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitors
- heteroarilamidas
- bicycles
- type
- glycine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una serie de heteroarilamidas (3.1.0)biciclicas sustituidas de fórmula I, en la que los grupos A, Q, X, Y, Z y R1-R5 se defienen como en la memoira descriptiva, que muestran actividad como inhibidores del transporte de glicina, a sus sales farmacéuticamente aceptables, a composiciones farmacéutica que las contienen, y a su uso para la potenciación de la cognición y el tratamiento de los síntomas positivos y negativos de la esquizofrenia y otras psicosis en mamíferos, incluyendo seres humanos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66947205P | 2005-04-08 | 2005-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29456A1 true UY29456A1 (es) | 2006-11-30 |
Family
ID=36649611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29456A UY29456A1 (es) | 2005-04-08 | 2006-04-05 | Heteroarilamidas(3.1.0)bicíclicas como inhibidores del transporte de glicina de tipo i |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20060229455A1 (es) |
| EP (1) | EP1869019B1 (es) |
| JP (1) | JP4193949B2 (es) |
| KR (1) | KR100969402B1 (es) |
| CN (1) | CN101189228A (es) |
| AP (1) | AP2007004198A0 (es) |
| AR (1) | AR056307A1 (es) |
| AU (1) | AU2006231917B2 (es) |
| BR (1) | BRPI0608148A2 (es) |
| CA (1) | CA2603939C (es) |
| CR (1) | CR9493A (es) |
| DK (1) | DK1869019T3 (es) |
| DO (1) | DOP2006000078A (es) |
| EA (1) | EA014311B1 (es) |
| ES (1) | ES2520015T3 (es) |
| GE (1) | GEP20105053B (es) |
| GT (1) | GT200600136A (es) |
| HN (1) | HN2006013804A (es) |
| IL (1) | IL186409A (es) |
| MA (1) | MA29672B1 (es) |
| MX (1) | MX2007012463A (es) |
| NL (1) | NL1031539C2 (es) |
| NO (1) | NO339422B1 (es) |
| NZ (1) | NZ563238A (es) |
| PE (1) | PE20061400A1 (es) |
| TN (1) | TNSN07380A1 (es) |
| TW (1) | TW200719890A (es) |
| UA (1) | UA88518C2 (es) |
| UY (1) | UY29456A1 (es) |
| WO (1) | WO2006106425A1 (es) |
| ZA (1) | ZA200708481B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
| WO2009131957A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
| FR2932479A1 (fr) * | 2008-06-13 | 2009-12-18 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU2009289784B2 (en) * | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| WO2010107115A1 (ja) | 2009-03-19 | 2010-09-23 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AR077472A1 (es) * | 2009-07-15 | 2011-08-31 | Taisho Pharmaceutical Co Ltd | Inhibidores de transportador de glicina |
| CA2779442A1 (en) | 2009-11-06 | 2011-05-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| JP2013249257A (ja) * | 2010-09-16 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| JP2013249258A (ja) * | 2010-09-17 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| WO2012036278A1 (ja) | 2010-09-17 | 2012-03-22 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| WO2012042539A2 (en) | 2010-09-28 | 2012-04-05 | Panacea Biotec Ltd | Novel bicyclic compounds |
| DK2909181T3 (da) * | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| MA39888A (fr) | 2014-04-24 | 2017-03-01 | Dart Neuroscience Cayman Ltd | Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1 |
| EP3215500A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted azetidinyl compounds as glyt1 inhibitors |
| KR20200110648A (ko) | 2017-12-05 | 2020-09-24 | 선오비온 파마슈티컬스 인코포레이티드 | 비라세믹 혼합물 및 이의 용도 |
| CN118955352A (zh) | 2017-12-05 | 2024-11-15 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| BR112021024224A2 (pt) | 2019-05-31 | 2022-04-26 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| MX2021014443A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| JP2022535893A (ja) | 2019-06-04 | 2022-08-10 | サノビオン ファーマシューティカルズ インク | 放出調節製剤およびその使用 |
| CN116212025A (zh) | 2020-01-09 | 2023-06-06 | 迪斯克医药公司 | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| KR20230051247A (ko) | 2020-08-13 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 정신분열병과 연관된 인지 손상의 치료 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK13092000A3 (sk) | 1998-03-06 | 2001-03-12 | Janssen Pharmaceutica N. V. | Inhibítory prenosu glycínu, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie |
| JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
| CA2468761A1 (en) | 2001-10-31 | 2003-05-08 | Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie | Novel anticancer compounds |
| FR2838739B1 (fr) | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| JP4732354B2 (ja) * | 2003-10-14 | 2011-07-27 | ファイザー・プロダクツ・インク | グリシン輸送阻害薬としての二環式［３．１．０］誘導体 |
| CN106434833A (zh) | 2004-05-23 | 2017-02-22 | 杰勒德·M·豪斯 | Theramutein调节剂 |
-
2006
- 2006-03-27 UA UAA200711021A patent/UA88518C2/ru unknown
- 2006-03-27 BR BRPI0608148-7A patent/BRPI0608148A2/pt not_active IP Right Cessation
- 2006-03-27 MX MX2007012463A patent/MX2007012463A/es active IP Right Grant
- 2006-03-27 ES ES06727516.4T patent/ES2520015T3/es active Active
- 2006-03-27 GE GEAP200610309A patent/GEP20105053B/en unknown
- 2006-03-27 WO PCT/IB2006/000947 patent/WO2006106425A1/en active Application Filing
- 2006-03-27 EA EA200701902A patent/EA014311B1/ru not_active IP Right Cessation
- 2006-03-27 JP JP2008504868A patent/JP4193949B2/ja not_active Expired - Fee Related
- 2006-03-27 DK DK06727516.4T patent/DK1869019T3/da active
- 2006-03-27 KR KR1020077025888A patent/KR100969402B1/ko active IP Right Grant
- 2006-03-27 CA CA2603939A patent/CA2603939C/en not_active Expired - Fee Related
- 2006-03-27 AU AU2006231917A patent/AU2006231917B2/en not_active Ceased
- 2006-03-27 AP AP2007004198A patent/AP2007004198A0/xx unknown
- 2006-03-27 EP EP06727516.4A patent/EP1869019B1/en active Active
- 2006-03-27 CN CNA2006800198904A patent/CN101189228A/zh active Pending
- 2006-03-27 NZ NZ563238A patent/NZ563238A/en not_active IP Right Cessation
- 2006-03-31 DO DO2006000078A patent/DOP2006000078A/es unknown
- 2006-04-05 UY UY29456A patent/UY29456A1/es unknown
- 2006-04-06 US US11/399,071 patent/US20060229455A1/en not_active Abandoned
- 2006-04-06 PE PE2006000374A patent/PE20061400A1/es not_active Application Discontinuation
- 2006-04-06 HN HN2006013804A patent/HN2006013804A/es unknown
- 2006-04-06 AR ARP060101362A patent/AR056307A1/es unknown
- 2006-04-06 GT GT200600136A patent/GT200600136A/es unknown
- 2006-04-07 TW TW095112431A patent/TW200719890A/zh unknown
- 2006-04-07 NL NL1031539A patent/NL1031539C2/nl not_active IP Right Cessation
-
2007
- 2007-10-03 NO NO20074993A patent/NO339422B1/no not_active IP Right Cessation
- 2007-10-04 ZA ZA200708481A patent/ZA200708481B/xx unknown
- 2007-10-07 IL IL186409A patent/IL186409A/en active IP Right Grant
- 2007-10-08 TN TNP2007000380A patent/TNSN07380A1/fr unknown
- 2007-10-08 MA MA30281A patent/MA29672B1/fr unknown
- 2007-11-01 CR CR9493A patent/CR9493A/es not_active Application Discontinuation
-
2010
- 2010-08-30 US US12/870,928 patent/US8124639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29456A1 (es) | Heteroarilamidas(3.1.0)bicíclicas como inhibidores del transporte de glicina de tipo i | |
| CR8333A (es) | Derivados biciclicos [3.1.0 ] como inhibidores del transportador de glicina | |
| UY29384A1 (es) | Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes. | |
| CO2018003565A2 (es) | Compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
| UY30759A1 (es) | Compuestos quimicos | |
| CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| SV2009003281A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa.0 | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
| CL2009001059A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras. | |
| ECSP088821A (es) | Derivados de tioxantina y su uso como inhibidores de la mpo | |
| ECSP056019A (es) | 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune | |
| PA8803201A1 (es) | Derivados acidos de cicloalquilamino | |
| UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
| UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
| CU20120002A7 (es) | DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA | |
| GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
| UY31141A1 (es) | Compuestos de piperidina y sus usos | |
| CL2008003576A1 (es) | Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria. | |
| SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
| UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20120426 |